<DOC>
	<DOCNO>NCT03063983</DOCNO>
	<brief_summary>Preclinical model show daily antiangiogenic regimen low-dose may effective chemotherapy-resistant tumor . The aim study evaluate efficacy maintenance therapy continuous oral cyclophosphamide methotrexate patient high grade , operable , metastatic osteosarcoma ( OST ) extremity . The primary end point event-free survival ( EFS ) randomization</brief_summary>
	<brief_title>Clinical Trial Evaluating Metronomic Chemotherapy Patients With Metastatic Osteosarcoma</brief_title>
	<detailed_description>The study design include backbone 10 week preoperative therapy use MAP ( high-dose methotrexate , cisplatin , doxorubicin dexrazoxane ) . Metastatic patient randomize high-dose chemotherapy 31 week ( arm 1 ) concomitant metronomic therapy ( MTX plus cyclophosphamide ) 31 week high-dose chemotherapy , follow 73 week metronomic therapy completion high-dose chemotherapy , total 104 week metronomic therapy ( arm 2 ) .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>A newly diagnose patient , previously untreated , high degree malignancy , confirm biopsy . Participant OST neoplasm also eligible Participant stag image study perform less four week . Otherwise , restaged If prechemotherapy amputation necessary , participant enter study exclude evaluation tumor necrosis grade accord Huvos , eligible survival analysis Participant age ≥ 16 year Karnofsky performance score &gt; 50 WHO / ECOG ≥ 2 patient &lt; 16 year Lansky performance score &gt; 50 . Participant performance score impair presence pathological fracture eligible Patients normal organic function Sexually active participant agree use contraceptive method throughout treatment Female participant negative pregnancy test If participant legal guardian refuse sign informed consent form / consent term include study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>metronomic therapy</keyword>
</DOC>